{"id":"NCT01215253","sponsor":"University of Rochester","briefTitle":"Ranolazine Implantable Cardioverter-Defibrillator Trial","officialTitle":"Late Sodium Current Blockade in High-Risk ICD Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2017-02-28","completion":"2017-02-28","firstPosted":"2010-10-06","resultsPosted":"2018-06-15","lastUpdate":"2018-08-27"},"enrollment":1012,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ischemic Cardiomyopathy","Nonischemic Cardiomyopathy","Heart Failure"],"interventions":[{"type":"DRUG","name":"Ranolazine","otherNames":["Ranexa"]}],"arms":[{"label":"Ranolazine","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs). This drug will be used with standard medications that is routinely prescribed in enrolled patients.","primaryOutcome":{"measure":"Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death","timeFrame":"2 years of follow-up on average","effectByArm":[{"arm":"Ranolazine","deltaMin":174,"sd":null},{"arm":"Placebo","deltaMin":198,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.117"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":20},"locations":{"siteCount":90,"countries":["United States","Canada"]},"refs":{"pmids":["38032582","35738852","30071993"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":510},"commonTop":["dizziness","nausea"]}}